The Human Genome Is Having Its Facebook Moment
By Whet Moser,
Chicago Magazine
| 08. 09. 2016
Untitled Document
In June, 4.1 petabytes of cancer data went online on a new platform, run by the University of Chicago, called the Genomic Data Commons. Four petabytes is about sixteen times all the information in the Library of Congress—but only about four percent of the data stored by Facebook as of 2012.
In other words, the data we generate about how we live our lives is much more vast and organized than the data about biological life itself, and the technology used to organize it is more seamless and sophisticated. But given the evolution of technology, that makes sense. Consider how we documented day-to-day life before smartphones and services like Facebook: you had to have a camera, which wrote to a card, from which you transferred photos to a hard drive. That recorded limited metadata, generally date and time and some information about the camera itself.
As phones got better cameras and those cameras were connected by software to the phone’s other features, pictures could go straight to the cloud with location data; software on the other end could...
Related Articles
By Jacob M. Apel, The Baltimore Sun | 08.16.2024
By Neha Kondaveeti, The Austin Chronicle | 08.16.2024
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...